Aquestive Therapeutics/$AQST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Ticker
$AQST
Sector
Primary listing
Employees
147
Headquarters
Website
AQST Metrics
BasicAdvanced
$529m
-
-$0.61
1.50
-
Price and volume
Market cap
$529m
Beta
1.5
52-week high
$7.55
52-week low
$2.93
Average daily volume
1.7m
Financial strength
Current ratio
4.1
Quick ratio
3.704
Long term debt to equity
-85.916
Total debt to equity
-127.976
Interest coverage (TTM)
-3.34%
Profitability
EBITDA (TTM)
-55.342
Gross margin (TTM)
63.45%
Net profit margin (TTM)
-137.08%
Operating margin (TTM)
-111.18%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-28.71%
Return on equity (TTM)
145.10%
Valuation
Price to revenue (TTM)
9.545
Price to book
-15.4
Price to tangible book (TTM)
-15.4
Price to free cash flow (TTM)
-10.827
Free cash flow yield (TTM)
-9.24%
Free cash flow per share (TTM)
-0.39
Growth
Revenue change (TTM)
-7.30%
Earnings per share change (TTM)
3.02%
3-year revenue growth (CAGR)
2.60%
3-year earnings per share growth (CAGR)
-1.54%
What the Analysts think about AQST
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
AQST Financial Performance
Revenues and expenses
AQST Earnings Performance
Company profitability
AQST News
AllArticlesVideos
Aquestive Therapeutics Q1 Earnings Call Highlights
MarketBeat·1 month ago
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
Business Wire·1 month ago
AQST DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs